Articles in this Issue

• Pharma Contract Services Consolidation Wave Continues

  Nigel Walker
  Contract service providers to the (bio)pharmaceutical industry must help their customers speed the development of new drugs while reducing costs.

• Evolving Role Of The Process Architect

  Peter Cramer
  Evolution in the life sciences industry is driving the need for new manufacturing paradigms based on advanced technologies.

• Managing the Complexity Of Global Clinical Logistics for Next Generation Personalized Medicines

  Wes Wheeler, Ariette van Strien
  To properly facilitate this, Supply Chain Logistics Providers must not only be experienced with all relevant customs regulations and the specialized requirements for shipping these sensitive materials, they must be adept at risk management and contingency planning to ensure that clinical trial materials are safeguarded throughout the delivery process.

• Mergers & Acquisitions: Combining Market Segments

  Guy Tiene, MA
  Nice Insight Is in Conversation With Dago Caceres, Marketing Director, and Gary Lord, Global Strategic Marketing Director at the Dow Chemical Company, to Discuss the Drivers of the merger between Dow and Dow Corning, and the positive impact the Move Will have on Dow’s Pharma customers.

• Building The Foundation of Japan’s Premier CDMO

  Jun Yokohama, Toshio Yoshioka
  Currently, the global pharmaceutical market is expanding at a robust compound annual growth rate (CAGR) of 6.3%, according to Evaluate Pharma, with global pharmaceutical R&D spending increasing annually at approximately 2.8%.

• Transient Transfection At a Large Scale For Flexibility in Clinical And Commercial Vector Manufacturing

  Richard O. Snyder, Ph.D., Scott Jeffers, Ying Cai
  The rapid progress of cell and gene therapies through clinical development is driving demand for late-stage clinical and commercial manufacturing capabilities.

• Russian Pharma Market Offers Great Potential for Local Manufacturers

  Renaud Bessière
  The Russian market presents new growth opportunities for pharmaceutical companies with manufacturing capabilities within the country.

• The CDMO and the International Supply Chain

  Cynthia A. Challener, Ph.D., Carrie Cao, Emilie Branch
  As a global supply chain becomes the new norm, local issues have increasingly entered the dialogue around production.

• Building Strategic Sponsor-CRO Partnerships

  Cynthia A. Challener, Ph.D., Carrie Cao, Emilie Branch
  Global CRO Market: Overview Driven by the growing number of clinical trials and demand for advanced medicines across the globe, the CRO market is projected to reach $59.42 billion by 2020 at a compound annual growth rate (CAGR) of 9.8% from 2015 to 2020, according to Zion Market Research.

• New Manufacturing Paradigms in an Evolving Pharma Industry

  Cynthia A. Challener, Ph.D., Carrie Cao, Emilie Branch
  The need for greater speed across all activities in the pharmaceutical industry not only impacts discovery and development of new drug candidates, but also the design, construction and validation of new facilities, and the upgrading of existing plants.

• Achieving a High Level Of Customer Service Through Lean Quality Management

  Warren Horton
  Providing customers with their order when they want it, at the right price and quantity, is only laying the foundation for excellent customer service.

• Oral Solid Dose Manufacturing Efficiency Is Driving New Attention To Plant Design

  Witold Lehmann
  Mapping out an effective, coherent, long-term manufacturing strategy is likely one of the more difficult tasks facing any drug owner or developer. For oral solid dose (OSD) drug manufacturers, the past 10-15 years have seen manufacturing strategies change drastically, with a focus on achieving more, with less.

• Fighting Prescription Drug Abuse With Demonstrated Abuse-deterrent Formulations

  Angela Moore
  As the number of opioid prescriptions in the US has climbed dramatically, so has the abuse and misuse of these drugs, leading to loss of life and significant social costs. The pharmaceutical industry, in conjunction with FDA, has focused on identifying approaches for the development of abuse-deterrent opioid formulations and methods for demonstrating their effectiveness.

• Combining Content and Research in a Single Website Platform

  Emilie Branch, Kshitij (TJ) Ladage
  The research enterprise of That’s Nice — Nice Insight — has grown signifi cantly over the past seven years and now encompasses our core Nice Insight Research Services, as well as Pharma’s Almanac, which offers rich data-driven content.

• Nice Insight Market Data

  The integration of the Pharma’s Almanac with Nice Insight was a clear next step, as both sites are powered by research.

• How important are international partnerships (with sponsor firms, service providers, engineering...

  Success in international markets is fundamental to the progression and growth of our pharmaceutical business. This demographic is driven by the geography of the market itself, in terms of current global pharmaceutical consumption and predicted regional growth, as well as the regulatory requirement for regional testing to support global and local product registration.

• The Road To Bio

  Safely over the bridge and through the verdant pasture land of New Jersey’s greater Princeton area, we were greeted by Envigo’s Joe Bedford with some sound advice on putting early development on the right road by meeting regulatory guidelines. Facing a minor run-in ourselves with the local regulatory agency shortly thereafter, we were grateful for Bedford’s timely advice at this early stage of our journey.